ArticleJournal for immunotherapy of cancer2023

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).

Karen A Autio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.